Gastroenterologist Dr. Austin Chiang has about a decade of experience as a physician influencer on social media. During a conference in Chicago, he encouraged more providers to share their expertise on social media. By having a presence on these platforms, healthcare professionals demonstrate their commitment to meeting patients where they are, he said.

Allurion Technologies has commercialized a gastric balloon in the form of a pill that patients swallow. But the weight loss platform from the now NYSE-listed company also includes AI-driven software that provides insights about a patient’s progress, technology with the potential for use alongside obesity drugs.

Medtronic recently received FDA approval for its MiniMed 780G system, which is an insulin pump that automatically adjusts and corrects type 1 diabetes patients’ glucose levels every five minutes. The news comes two years after Medtronic submitted the system for FDA approval and three years after the company began selling the product in Europe.

Nvidia and Medtronic recently announced a collaboration focused on embedding AI into medical devices. The two companies plan to create marketplace for AI applications that will allow developers and clinicians to develop their own algorithms to use on Medtronic’s medical devices.

Allurion Technologies has developed a gastric balloon that does not require surgery. The merger deal taking Allurion public comes as the company continues global commercialization of its technology.

Abbott recently earned FDA approval for its latest transcatheter aortic valve implantation (TAVI) system, which is named Navitor. Abbott will have to fight for its place the U.S. TAVI device space, as the systems made by Edwards and Medtronic have a steadfast command of the market share.

The innovation platform promises to match entrepreneurs with the resources they need to advance treatments for stroke care but also to help the device maker process all the new ideas it sees.

Mike Matson evaluated two earlier negative bits of information along with Thursday’s revenue and earnings-per-share miss to conclude that Medtronic’s stock, which has held up despite recent market swings, needs to be downgraded to a “hold” from a “buy”.

An infographic illustrates how Medtronic’s AccuRhythm AI suppresses false alerts while maintaining sensitivity.

To get approval for the deal, Medtronic agreed to sell an Intersect subsidiary to soothe the FTC’s concerns.

Geoff Martha participated in the 40th annual J.P. Morgan Healthcare conference virtually explaining key decisions, accepting responsibility for a trifecta of bad news while also signaling that all will be well in the future at the Dublin-based medtech giant.

The company received a warning letter on Wednesday related to inadequate quality requirements at the headquarters for its diabetes business. It comes after Medtronic expanded a recall of its MiniMed 600 series insulin pumps.

Medtronic is expanding a recall of two of its MiniMed 600 series insulin pumps after reports found several had broken retainer rings cracked, resulting in insulin doses that were too high or too low. 

Investors had long expected Intersect ENT to be an acquisition target before Medtronic announced its plans to buy the company last week. Better reimbursement for Intersect ENT’s products and elective procedures returning over the summer months might have helped the deal cross the finish line. 

Join our live webinar with top MedTech sales experts to learn how to succeed in the digital revolution of medical device and healthcare sales.

Medtronic suffered a shocking setback back in 2014 when its Symplicity 3 pivotal trial failed to meet its primary endpoint of reducing blood pressure meaningfully. Now it is gearing up to present new data to the FDA.

With a recent acquisition from France, Medtronic is aiming to leverage AI in the world of spine surgery and integrate the system with its robot.

In a public health crisis such as the Covid-19 pandemic, each healthcare vertical is playing […]

Our latest eBook offers examples of how some of the players in healthcare are thinking about AI, seeking to apply it across care coordination, drug development and early detection of disease and how to address some of the challenges the technology poses for adoption and implementation.

Ishrak has led the company for nearly nine years and will retire at the end of the fiscal year in late April turning over the reins to his deputy Geoff Martha who, like Ishrak, came to Medtronic from GE Healthcare.

Medtronic’s new deep brain stimulation device, Percept, reads brain signals to better optimize treatment. Traditionally, physicians adjust DBS signals based on a patient’s diary entries, which can be imprecise.

Venclose has received $27 million in Series C funding to expand market share for it venous reflux therapy. This RF ablation device is designed to simplify treatment and reduce procedure times.

Don’t mistake Stryker’s latest $500 million deal in the spine market as a simple tuck-in acquisition, says one analyst while another says it could help Stryker give Medtronic a run for its money.

After diabetes, Medtronic is looking to leverage AI through a distribution agreement with Viz.ai, which uses the technology to streamline stroke care.

The San Diego-based company has is in the midst of one of the most precipitous turnarounds in the medical device industry and is well positioned to grow alongside the expanding insulin pump market.

Medtronic announced data at the annual meeting of the American Diabetes Association on Monday that shows that people using its AI-powered Sugar.IQ diabetes assistant have better control of their blood glucose levels.

On the day that an FDA official exhorts industry to develop interoperable diabetes devices, Medtronic announces that it is teaming up with a nonprofit group to do just that.

MedCity News caught up with Omron Healthcare CEO Ranndy Kellogg at the the AdvaMed Digital MedTech Conference in San Francisco to speak about the company’s new products, emerging business lines and how collaboration with other companies have driven recent innovation.

Dexcom’s executives lay out the land in terms of competition in the standalone continuous glucose monitoring market while Medtronic CEO responds.

While the development of renal denervation technologies stalled after a failed Medtronic study in 2014, recent positive research results have led to increasing interest – and investment –  in the space.